A new study has found that women chose not to go ahead with contralateral prophylactic mastectomy (CPM) if their surgeon recommended against it.
Contralateral prophylactic mastectomy (CPM)—removal of the healthy breast along with the cancerous breast—has been rising over the years, even among women who are at a low risk of developing contralateral cancer. However, a new study has found that women chose not to go ahead with the procedure if their surgeon recommended against it.
“That 1 in 6 breast cancer patients chose bilateral mastectomy is really striking. We knew it was increasing, but I don’t think many of us realized just how frequent this is,” study author Reshma Jagsi, MD, DPhil, professor and deputy chair of radiation oncology at the University of Michigan, said in a statement.
For their study, published in JAMA Surgery, researchers sent a survey to 3631 women, identified via the Surveillance Epidemiology and End Results registries, who were newly diagnosed with unilateral stage 0, I, or II breast cancer between July 2013 and September 2014. The survey included questions on surgical decisions, motivations for those decisions, and knowledge. Subsequent analysis of the data identified factors that were associated with:
Only 71% (2578) of women who received the survey responded—of these, 2402 who did not have bilateral disease, and for whom the surgery type was known, were included in the final analysis. Nearly 44% (1301) of these patients considered CPM, 38% (395) of whom know that CPM does not improve survival for all women with breast cancer. It is noteworthy that more than 60% of women had a poor understanding of the benefits rendered by this procedure.
The analysis showed that age, white race, higher education level, family history, and private insurance were associated with CPM. Of the 1569 (65.5%) patients without a high genetic risk or an identified mutation, 598 (39.3%) noted that their surgeon had recommended against the procedure—only 12 (1.9%) of these women then decided to go ahead with the surgery. However, among the 746 (46.8%) of women who did not receive a recommendation from their surgeon, 148 (19.0%) underwent CPM.
According to Jagsi, it’s not surprising that newly diagnosed breast cancer patients might find it difficult to absorb this complex information, considering the emotional upheaval they were going through at that time. “It seems logical that more aggressive surgery should be better at fighting disease—but that’s not how breast cancer works. It’s a real communication challenge,” she said.
The authors write that their survey showed patients are not very knowledgeable about CPM, and discussions with their surgeons were incomplete. Considering that women whose surgeons recommended against undergoing CPM primarily chose not to undergo the procedure indicates that effective patient-physician communication can reduce potential overtreatment.
Reference
Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer [published December 21, 2016]. JAMA Surg. doi: 10.1001/jamasurg.2016.4749.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More